30Apr/21

Immunogenicity, a Headache of ADC Developers

April 30, 2021Antibody-drug Conjugates ResearchADC, Anti-drug antibodybioadc

Protein drugs have the potential to induce immunogenicity, whose consequences may affect the efficacy or even be life-threatening. New models of biotherapy, such as antibody-conjugated (ADC) drugs, fusion proteins, and polyethylene glycolization,Read More…

29Mar/21

Fast-Tracking ADC Drugs Manufacturing and Production Technology

March 29, 2021UncategorizedADC Drugs, Antibody Conjugation Technique, DAR, site-specific conjugation, unnatural amino acid conjugatebioadc

When we get an ideal candidate for ADC, the next step is to consider how to scale it up. This step is important because it is directly related to the post-market marketRead More…

29Mar/21

Overview: Mechanism of Action of ADC

March 29, 2021UncategorizedAction of ADCbioadc

Specific Binding ADC drugs specifically bind to antigenic epitopes of cancer cells through their “guiding” antibodies, and enter into cancer cells through antigen-mediated endocytosis, then release the “warheads” – highly active cytotoxicRead More…

29Mar/21

Comprehensively Review Targets for ADC

March 29, 2021ReviewADC targets, CD19, CD30, CD37, Trop2bioadc

At present, ADC drugs are mainly used in the field of tumors, so antigenic targets are required to be highly expressed in tumor cells but with low or no expression in normalRead More…

31Jan/21

Clinical Results of immunogenicity of Multiple ADC Molecules

January 31, 2021Antibody-drug Conjugates Research, NewsADA, ADCs, Anti-drug antibodybioadc

Protein drugs have high risks of inducing immunogenicity, which may affect the efficacy or even be life-threatening. Most biotherapies, such as antibody-drug conjugates (ADCs), fusion proteins, and polyethylene glycolization, carry unnatural humanRead More…

16Dec/20

Booming 2020 for ADC—Achieved $40 billion Trade

December 16, 2020UncategorizedADC, ADC trade, HER2, HER3, Trop-2bioadc

ADC drugs are undoubtedly the focus of many pharmaceutical companies competing for layout in 2020, reaching $40 billion deal in less than a year. AstraZeneca built a partnership with the Daiichi SankyoRead More…

30Nov/20

Analysis of the ADCs Drugs Approved by FDA

November 30, 2020ReviewADC, CD30, FDA ADCsbioadc

Antibody-drug conjugate (ADC) has achieved great progress in the past decade. So far, ten ADC drugs have been approved by the FDA, of which five were approved in 2019 and 2020, andRead More…

13Oct/20

Design ADC with Creative Biolabs – Episode II

October 13, 2020Reviewadc Conjugate, ADC design, antibody of ADCbioadc

In the last blog, we learned that the main feature of ADC candidate target antigen is that it needs to be highly expressed on the surface of tumor cells and not expressedRead More…

17Sep/20

Design ADC with Creative Biolabs-Episode I

September 17, 2020ReviewADC design, DAR, tumor targetbioadc

As we all known, antibody-drug conjugate (ADC) is a drug obtained by chemical conjuagtion of antibody, linker and cytotoxin. Compared with simple monoclonal antibodies, ADC has better targeting and more efficient killingRead More…

17Sep/20

Blockbuster Deal for ADC: Merck Sharp & Dohme and Seattle Genetics Reach a $4.5 Billion Partnership

September 17, 2020NewsADC, HER2, ladiratuzumab vedotin, LIV-1, Trop-2bioadc

On September 13, 2020, Gilead announced that it would acquire Immunomedics, whose core product is Trop-2 ADC drug Trodelvy, for more than $20 billion. On September 14, 2020, Merck Sharp & DohmeRead More…